Actuate Therapeutics, Inc (NASDAQ:ACTU) IPO will take place July, 24 on the NASDAQ exchange under the ticker ACTU.
The company is offering shares at an expected price between $8.00 and $10.00 per share with an insider lock-up period of 180 days ending on January 20, 2025.
See also: Benzinga IPO Calendar
About Actuate Therapeutics, Inc
Actuate Therapeutics, Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.